You have full text access to this OnlineOpen article

Cancer

Cover image for Vol. 118 Issue 21

1 November 2012

Volume 118, Issue 21

Pages 5183–5450, E1–E2

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. You have free access to this content
      Hypogonadism related to crizotinib therapy : Implications for patient care (pages E1–E2)

      Suresh S. Ramalingam and Alice T. Shaw

      Article first published online: 4 APR 2012 | DOI: 10.1002/cncr.27561

      This Web-only perspective commentary titled, “Hypogonadism Related to Crizotinib Therapy: Implications for Patient Care,” discusses a previously unreported side effect of crizotinib use in males for treatment of nonsmall cell lung cancer.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. You have full text access to this OnlineOpen article
      Data for cancer comparative effectiveness research : Past, present, and future potential (pages 5186–5197)

      Anne-Marie Meyer, William R. Carpenter, Amy P. Abernethy, Til Stürmer and Michael R. Kosorok

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27552

      The objective of this article is to systematically characterize and evaluate data available for cancer comparative effectiveness research. The authors present a data ontology, which organizes and describes strengths and weaknesses of currently available data, and proceed with recommendations for future data resource development.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis (pages 5198–5209)

      Fang Nie, Jian Yang, Song Wen, Yan-Li An, Jie Ding, Sheng-Hong Ju, Zhen Zhao, Hua-Jun Chen, Xin-Gui Peng, Stephen T. C. Wong, Hong Zhao and Gao-Jun Teng

      Article first published online: 17 APR 2012 | DOI: 10.1002/cncr.27553

      Epidermal growth factor receptor (EGFR) plays more important roles in cell migration and invasion to the brain than it plays in cell proliferation progression in breast cancer brain-seeking cells. The current findings provide new evidence of the potential value of EGFR inhibition in treating brain-metastatic breast cancer.

    2. You have full text access to this OnlineOpen article
      Clinical significance of large rearrangements in BRCA1 and BRCA2 (pages 5210–5216)

      Thaddeus Judkins, Eric Rosenthal, Christopher Arnell, Lynn Anne Burbidge, Wade Geary, Toby Barrus, Jeremy Schoenberger, Jeffrey Trost, Richard J. Wenstrup and Benjamin B. Roa

      Article first published online: 27 APR 2012 | DOI: 10.1002/cncr.27556

      Large rearrangements constitute between 5.9% and 9.9% of mutations in a large cohort of hereditary breast and ovarian cancer patients undergoing clinical testing for BRCA1 (breast cancer 1, early onset) and BRCA2 (breast cancer 2, early onset) genes, with significant differences in the BRCA1/2 mutation profiles in patients of different risk groups and ancestries. Comprehensive large rearrangement testing in conjunction with full gene sequencing is an appropriate strategy for clinical BRCA1/2 analysis.

    3. Endocrine Disease
      You have full text access to this OnlineOpen article
      Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene (pages 5217–5226)

      Bin Xu, Wen-yan Zheng, Da-yong Jin, Dan-song Wang, Xin-yuan Liu and Xin-yu Qin

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27535

      Lipocalin-2 has antitumor effects in pancreatic cancer. A lipocalin-2-expressing oncolytic adenovirus, ZD55-lipocalin-2, produces excellent antitumor effects on pancreatic cancer.

    4. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Clinical significance of gastritis cystica profunda and its association with Epstein-Barr virus in gastric cancer (pages 5227–5233)

      Min-Gew Choi, Ji Yun Jeong, Kyoung-Mee Kim, Jae Moon Bae, Jae Hyung Noh, Tae Sung Sohn and Sung Kim

      Article first published online: 17 APR 2012 | DOI: 10.1002/cncr.27541

      Patients who have gastric cancer with gastritis cystica profunda (GCP) have clinicopathologic features distinct from those observed in patients without GCP, suggesting different pathways of gastric carcinogenesis. GCP also is associated significantly with Epstein-Barr virus-positive gastric cancers, and its possible role as a premalignant lesion needs to be clarified.

    5. You have full text access to this OnlineOpen article
      Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma (pages 5234–5244)

      Peter F. Lenehan, Lisa A. Boardman, Douglas Riegert-Johnson, Giovanni De Petris, David W. Fry, Jeanne Ohrnberger, Eugene R. Heyman, Brigitte Gerard, Arpit A. Almal and William P. Worzel

      Article first published online: 17 MAY 2012 | DOI: 10.1002/cncr.27628

      The first tumor gene-based prognostic assay (OncoDefender-CRC) for both stage I colorectal cancer and stage II colon cancer has been generated and externally validated. It outperforms standard clinicopathologic prognostic criteria and identifies those patients most likely to develop recurrent disease within 3 years after curative surgery and who, thus, are most likely to benefit from adjuvant treatment.

    6. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Utility of serum tumor markers during surveillance for stage I seminoma (pages 5245–5250)

      Danny Vesprini, Peter Chung, Shaun Tolan, Mary Gospodarowicz, Michael Jewett, Martin O'Malley, Joan Sweet, Malcolm Moore, Tony Panzarella, Jeremy Sturgeon, Linda Sugar, Lynn Anson-Cartwright and Padraig Warde

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27539

      In patients with stage I seminoma who are managed with surveillance, following serum tumor marker levels does not aid in the early diagnosis of disease relapse and, thus, can be safely discontinued.

    7. Head and Neck Disease
      You have full text access to this OnlineOpen article
      DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma (pages 5251–5264)

      Tomofumi Hamada, Masahiro Nomura, Yoshiaki Kamikawa, Norishige Yamada, Surinder K. Batra, Suguru Yonezawa and Kazumasa Sugihara

      Article first published online: 20 MAR 2012 | DOI: 10.1002/cncr.27542

      To the authors' knowledge, the current study is the first to provide clinical evidence that aberrant expression of DF3/MUC1 is an independent prognostic factor indicating poor prognosis in patients with oral squamous cell carcinoma (OSCC). DF3/MUC1 is a risk factor for predicting subsequent lymph node metastasis in patients with OSCC and therefore can influence decisions regarding the need for elective neck dissection.

    8. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy (pages 5265–5269)

      Marzia Defina, Micaela Ippoliti, Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, Rosaria Crupi, Mario Tiribelli, Massimo Breccia, Marzia Salvucci, Lara Aprile, Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria and Monica Bocchia

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27506

      In patients with chronic myeloid leukemia who are treated with first-line nilotinib and are in complete cytogenetic response, residual clusters of differentiation 34–positive, Philadelphia chromosome–positive (CD34+/Ph+) stem cells are rarely detected. This may suggest that the fast inhibitory activity displayed by nilotinib on the bulk of chronic myeloid leukemia affects progenitor cells as well.

    9. You have full text access to this OnlineOpen article
      Human immunodeficiency virus-associated plasmablastic lymphoma : Poor prognosis in the era of highly active antiretroviral therapy (pages 5270–5277)

      Jorge J. Castillo, Michael Furman, Brady E. Beltrán, Michele Bibas, Mark Bower, Weina Chen, José L. Díez-Martín, Jane J. Liu, Roberto N. Miranda, Silvia Montoto, Nahid M. Nanaji, José-Tomás Navarro, Adam C. Seegmiller and Julie M. Vose

      Article first published online: 17 APR 2012 | DOI: 10.1002/cncr.27551

      On the basis of the results from this multi-institutional, retrospective study, patients with human immunodeficiency virus-associated plasmablastic lymphoma have a poor prognosis in the highly active antiretroviral therapy era, regardless of the intensity of chemotherapy.

    10. You have full text access to this OnlineOpen article
      Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia (pages 5278–5282)

      Martha Arellano, Suchita Pakkala, Amelia Langston, Mourad Tighiouart, Lin Pan, Zhengjia Chen, Leonard T. Heffner, Sagar Lonial, Elliott Winton and H. Jean Khoury

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27494

      Early blast clearance measured on daily complete blood counts is a strong predictor of remission, and relapse-free and overall survival in newly diagnosed acute myeloid leukemia. Measurement of peripheral blood blasts can be an encouraging early measure of treatment response in patients with newly diagnosed acute myeloid leukemia who are undergoing induction chemotherapy.

    11. You have full text access to this OnlineOpen article
      Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment (pages 5283–5292)

      Alfonso Quintás-Cardama, Yi Hua Qiu, Sean M. Post, Yiqun Zhang, Chad J. Creighton, Jorge Cortes and Steven M. Kornblau

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27568

      Reverse phase protein array profiling defines a specific set of proteins associated with the transformation from chronic phase to advanced phase chronic myeloid leukemia (CML). Some of these proteins also are overexpressed in CML stem cells. These results may unveil important targets to pharmacologically eradicate minimal residual disease in CML.

    12. Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis : A retrospective analysis of efficacy, safety, and survival benefits (pages 5293–5301)

      Joanne Chiu, Yuen Fong Tang, Tzy-Jyun Yao, Ashley Wong, Hilda Wong, Roland Leung, Pierre Chan, Tan To Cheung, Albert C. Chan, Roberta Pang, Sheung-Tat Fan, Ronnie Poon and Thomas Yau

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27543

      Patients with Child-Pugh class A and B cirrhosis tolerated sorafenib similarly and derived similar survival benefit. Among patients with Child-Pugh class B disease, most benefits were observed in patients with a score of 7.

    13. Lung Disease
      You have free access to this content
      Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer (pages 5302–5309)

      Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman and D. Ross Camidge

      Article first published online: 4 APR 2012 | DOI: 10.1002/cncr.27450

      Crizotinib therapy causes rapid suppression of testosterone levels in men. The site of action must include a central (hypothalamic or pituitary) effect, but additional direct testicular effects cannot be excluded.

  5. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. Disease Site

      Skin
      You have full text access to this OnlineOpen article
      Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors (pages 5310–5319)

      Glen J. Weiss and Ronald L. Korn

      Article first published online: 17 APR 2012 | DOI: 10.1002/cncr.27532

      Metastatic basal cell carcinoma is a rare presentation of a common cancer. In this report, basal cell carcinoma epidemiology and pathogenesis, the hedgehog signaling pathway and inhibitors, and radiographic features of basal cell carcinoma are reviewed.

  6. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. Disease Site

      Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging (pages 5320–5330)

      Jeffrey K. Mito, Jorge M. Ferrer, Brian E. Brigman, Chang-Lung Lee, Rebecca D. Dodd, William C. Eward, Lisa F. Marshall, Kyle C. Cuneo, Jessica E. Carter, Shalini Ramasunder, Yongbaek Kim, W. David Lee, Linda G. Griffith, Moungi G. Bawendi and David G. Kirsch

      Article first published online: 21 MAR 2012 | DOI: 10.1002/cncr.27458

      The presence of microscopic residual sarcoma left in the tumor bed of patients is associated with local failure, the development of distant metastases, and disease-specific survival. We use an imaging system targeting cathepsin proteases for real-time intraoperative imaging in mice to detect and remove microscopic residual sarcoma in vivo.

    2. You have full text access to this OnlineOpen article
      Comparing central nervous system (CNS) and extra-CNS hemangiopericytomas in the Surveillance, Epidemiology, and End Results program : Analysis of 655 patients and review of current literature (pages 5331–5338)

      William A. Hall, Arif N. Ali, Norleena Gullett, Ian Crocker, Jerome C. Landry, Hui-Kuo Shu, Roshan Prabhu and Walter Curran

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27511

      In this analysis, the authors compare the outcomes of 655 patients with central nervous system (CNS) and extra-CNS hemangiopericytomas (HPCs) in the Surveillance, Epidemiology, and End Results program database. A highly statistically significant difference in outcomes between patients with CNS and those with extra-CNS HPCs is presented along with a review of the current literature.

    3. You have full text access to this OnlineOpen article
      Incidence of soft tissue sarcoma and beyond : A population-based prospective study in 3 European regions (pages 5339–5348)

      Giuseppe Mastrangelo, Jean-Michel Coindre, Françoise Ducimetière, Angelo Paolo Dei Tos, Emanuela Fadda, Jean-Yves Blay, Alessandra Buja, Ugo Fedeli, Luca Cegolon, Alvise Frasson, Dominique Ranchère-Vince, Cristina Montesco, Isabelle Ray-Coquard and Carlo Riccardo Rossi

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27555

      Visceral sarcomas are not reported in cancer statistics. Sex hormones and many chemicals that act as endocrine disruptors may be involved in sarcoma carcinogenesis.

    4. You have full text access to this OnlineOpen article
      Leiomyosarcoma and sarcoma with myogenic differentiation : Two different entities or 2 faces of the same disease? (pages 5349–5357)

      Chiara Colombo, Rosalba Miceli, Paola Collini, Stefano Radaelli, Elena Palassini, Silvia Stacchiotti, Marco Fiore, Luigi Mariani, Paolo G. Casali and Alessandro Gronchi

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27569

      Sarcoma with myogenic differentiation and leiomyosarcoma have different natural histories and sensitivity to therapies. These entities should be considered different diseases, and patients with such tumors should receive different therapies.

    5. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer (pages 5358–5365)

      Yingwei Qi, Katie L. Allen Ziegler, Shauna L. Hillman, Mary W. Redman, Steven E. Schild, David R. Gandara, Alex A. Adjei and Sumithra J. Mandrekar

      Article first published online: 20 MAR 2012 | DOI: 10.1002/cncr.27528

      The authors investigate the impact of determining the date of disease progression on progression-free survival (PFS) estimates in phase 2 trials of patients with advanced lung cancer, and the results indicate that the magnitude of difference in PFS estimates between various approaches is large enough to alter trial conclusions. Therefore, it is critical to use standards for determining the date of disease progression, perform sensitivity analyses, and utilize randomized trial design when designing phase 2 trials and reporting efficacy using PFS-based endpoints in advanced lung cancer.

    6. Disparities Research
      You have full text access to this OnlineOpen article
      Enhancing life after cancer in diverse communities (pages 5366–5373)

      Judith S. Kaur, Kathryn Coe, Julia Rowland, Kathryn L. Braun, Francisco A. Conde, Linda Burhansstipanov, Sue Heiney, Marjorie Kagawa-Singer, Qian Lu and Catherine Witte

      Article first published online: 20 MAR 2012 | DOI: 10.1002/cncr.27491

      Although large numbers of cancer survivors exist in every community, including minority communities, there is a significant gap in knowledge regarding best practices for these patients. This article describes some specifically tailored interventions that may be useful to a wide range of providers working with underserved populations.

    7. Epidemiology
      You have full text access to this OnlineOpen article
      Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk (pages 5374–5383)

      John Charles A. Lacson, Joshua D. Carroll, Ellenie Tuazon, Esteban J. Castelao, Leslie Bernstein and Victoria K. Cortessis

      Article first published online: 10 SEP 2012 | DOI: 10.1002/cncr.27554

      In a population-based case-control study of testis cancer, marijuana use is associated with a 3-fold increased risk of nonseminomatous germ cell tumors. This result agrees with 2 earlier reports and further implicates exogenous compounds that act on the endocrine system in testicular carcinogenesis.

    8. You have full text access to this OnlineOpen article
      Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case–control study (pages 5384–5394)

      Paige M. Bracci, Mi Zhou, Scott Young and Joseph Wiemels

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27538

      This study contributes to growing evidence that cancer-related host immune-response factors may be useful diagnostic screening tools and prognostic indicators for pancreatic cancer. Further critical assessment is needed of autoantibody panels for detection of tumor-associated antigens for diagnosis, prognosis, and immunotherapy of pancreatic and other cancers.

    9. You have full text access to this OnlineOpen article
      Does skin cancer screening save lives? : An observational study comparing trends in melanoma mortality in regions with and without screening (pages 5395–5402)

      Alexander Katalinic, Annika Waldmann, Martin A. Weinstock, Alan C. Geller, Nora Eisemann, Ruediger Greinert, Beate Volkmer and Eckhard Breitbart

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27566

      After the development and introduction of population-based skin cancer screening in 2003/2004 in Schleswig-Holstein, Germany, a substantial and significant decline in melanoma mortality (−7.5% per year for men, −7.1% per year for women) is observed, whereas the adjoining regions have changed little. Taking several causes, possible biases, and confounders into account, the most likely explanation for the observed decline in melanoma mortality that remains is the skin cancer screening with its associated activities.

    10. Medical Oncology
      You have full text access to this OnlineOpen article
      A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies (pages 5403–5413)

      Michael J. Pishvaian, John L. Marshall, Andrew J. Wagner, Jimmy J. Hwang, Shakun Malik, Ion Cotarla, John F. Deeken, A. Ruth He, Hirut Daniel, Abdel-Baset Halim, Hamim Zahir, Catherine Copigneaux, Kejian Liu, Robert A. Beckman and George D. Demetri

      Article first published online: 8 MAY 2012 | DOI: 10.1002/cncr.27526

      In this phase 1 study of efatutazone, a novel thiazolidinedione, fluid retention, manageable by diuretics, is a common side effect, and broad anticancer activity is demonstrated. Correlative studies show that tumor expression of peroxisome proliferator-activated receptor gamma and the retinoid-X receptor may serve as molecular markers to predict clinical benefit.

    11. Outcomes Research
      You have full text access to this OnlineOpen article
      Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer (pages 5414–5423)

      Jean M. Butte, Mithat Gonen, Peirong Ding, Karyn A. Goodman, Peter J. Allen, Garrett M. Nash, Jose Guillem, Philip B. Paty, Leonard B. Saltz, Nancy E. Kemeny, Ronald P. DeMatteo, Yuman Fong, William R. Jarnagin, Martin R. Weiser and Michael I. D'Angelica

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27567

      The optimal combination of therapies for patients with resectable synchronous liver metastases from rectal cancer is unknown, and the pattern of recurrence has been poorly studied. This study demonstrates that systemic recurrences overwhelmingly exceed pelvic recurrence, and the selective exclusion of radiotherapy may be considered in this subset of patients.

    12. Radiation Oncology
      You have full text access to this OnlineOpen article
      Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization (pages 5424–5431)

      Jin-Kyu Kang, Mi-Sook Kim, Chul Koo Cho, Kwang Mo Yang, Hyung Jun Yoo, Jin Ho Kim, Sun Hyun Bae, Da Hoon Jung, Kum Bae Kim,, Dong Han Lee, Chul Ju Han, Jin Kim, Su Cheol Park and Young Han Kim

      Article first published online: 8 MAY 2012 | DOI: 10.1002/cncr.27533

      Stereotactic body radiation therapy after incomplete transarterial chemoembolization for inoperable hepatocellular carcinoma achieves promising response and local control rates. On the basis of the results from this study, a modified, multi-institutional, phase 2 trial to reduce gastrointestinal toxicities is mandatory.

    13. You have full text access to this OnlineOpen article
      Life years lost—comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale (pages 5432–5440)

      N. Patrik Brodin, Ivan R. Vogelius, Maja V. Maraldo, Per Munck af Rosenschöld, Marianne C. Aznar, Anne Kiil-Berthelsen, Per Nilsson, Thomas Björk-Eriksson, Lena Specht and Søren M. Bentzen

      Article first published online: 19 APR 2012 | DOI: 10.1002/cncr.27536

      A framework for calculating the estimated life years lost attributable to late toxicity after radiotherapy is presented. The life years lost measure allows direct comparison between various late effects, and the authors demonstrate how such a measure can be used to prioritize between the risk of cardiac events and secondary cancer induction.

    14. You have full text access to this OnlineOpen article
      Hearing preservation in patients with unilateral vestibular schwannoma who undergo stereotactic radiosurgery : Reinterpretation of the auditory brainstem response (pages 5441–5447)

      Jung Ho Han, Dong Gyu Kim, Hyun-Tai Chung, Sun Ha Paek, Chul-Kee Park, Chae-Yong Kim, Young-Hoon Kim, Jin Wook Kim, Yong Hwy Kim, Sang Woo Song, In Kyung Kim and Hee-Won Jung

      Article first published online: 8 MAY 2012 | DOI: 10.1002/cncr.27501

      The authors suggest a classification system based on the hearing outcomes of patients who undergo stereotactic radiosurgery for vestibular schwannoma. This system may guide an individualized treatment strategy for hearing preservation in patients with vestibular schwannoma.

  7. Errata

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Review Articles
    7. Original Articles
    8. Errata
    1. You have free access to this content
    2. You have free access to this content
      Erratum (page 5448)

      Article first published online: 17 APR 2012 | DOI: 10.1002/cncr.27534

      This article corrects:
    3. You have free access to this content
      Erratum (pages 5448–5449)

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27558

      This article corrects:

      Adenoid cystic carcinoma of the head and neck

      Vol. 118, Issue 18, 4444–4451, Article first published online: 31 JAN 2012

    4. You have free access to this content
      Erratum: Survivorship navigation outcome measures: A report from the ACS Patient Navigation Working Group on Survivorship Navigation (page 5450)

      Article first published online: 20 MAR 2012 | DOI: 10.1002/cncr.27546

      This article corrects:

      Survivorship navigation outcome measures1234

      Vol. 117, Issue S15Issue Supplement 15, 3573–3582, Article first published online: 20 JUL 2011

    5. You have free access to this content

SEARCH

SEARCH BY CITATION